Domainex's newsletter brings you up to speed on the latest announcements from the team.

No images? Click here

Domainex - Enrich your medicines pipeline
 

Domainex newsletter

All the latest news and industry insights from the Domainex team

 
 
 
Tom headshot

Tom Mander, CEO

International collaboration and awards success with more to come in 2024

As we approach the conclusion of another eventful year, it's a perfect moment to pause and reflect on the journey we've undertaken. Although 2023 is not yet complete, it has been a year filled with awards and acknowledgments for the work done here at Domainex. The third and fourth quarters have been no exception, marked by significant achievements.

We were delighted to launch our new Direct-to-Biology service earlier this month and look forward to applying this to more of our clients’ drug discovery projects. Please do get in touch if you would like to find out more about this approach which combines plate-based chemistry with rapid screening to accelerate research programmes.

I extend my gratitude to our shareholders for their unwavering support in our growth, and I take immense pride in acknowledging the hard work and dedication of my colleagues. Without their commitment, we would not be in this exciting position, looking forward to 2024 with ambitious plans. I would also like to express our appreciation to all our clients, both longstanding and new, for entrusting us with such exciting projects. We eagerly anticipate our continued collaboration in 2024.

Domainex celebrates success with multiple industry awards and outlines exciting future plans

Domainex team at an awards ceremony

We are thrilled to announce our recent success in multiple prestigious business awards. On top of the King’s Award for Enterprise that Domainex was awarded in April this year, we have been further recognised for our commitment to excellence and innovation.

  • Life Science Scale-Up at the Business Weekly Awards  
  • Gold for High Growth Business of the Year and Silver for Business of the Year (>50 employees) at the Cambridge Independent SME Awards 
Read more
 
Direct to biology logo
 

Domainex launches Direct to Biology service

Partner with Domainex and let us revolutionise your drug discovery process by applying our Direct to Biology expertise to your project. By combing plate-based chemistry with rapid screening, we will open up a galaxy of opportunity for you!

 
Domainex down under
 

Domainex down under

Tom Mander flew to Australia earlier this month to give a seminar titled ‘Building a brighter future for drug discovery at the University of South Australia’. He also attended the HIT Identification Symposium in Melbourne and AusBioTech in Brisbane.

 
Domainex presenting a scientific poster
 

Forging powerful connections 

Domainex scientists attended the SCI-RSC 22nd Medicinal Chemistry Symposium where Anna Hopkins presented a poster on the identification of novel hit chemotypes by covalent fragment screening and binding site identification using proteolytic digestion and high-resolution LCMS.

We have attended numerous other events including BioEurope, Discovery on Target, Pharma Integrates and Genesis.

 
Domainex football team
 

Out of the lab and onto the pitch

The Domainex football team played in a charity match against Charles River Laboratories winning 6-4 and raising money for SNAP charity, a local charity for families with children and young people who have any additional need or disability.

 
team in the wellbeing garden
 

Bringing new life to Sawston Village College's wellbeing garden

And finally the CSR committee at Domainex organised for a group of volunteers to go to Sawston Village College  to help revive their wellbeing garden. The wellbeing garden was widely used by teachers and students as a place to relax and escape the stresses of modern life but needed some TLC. Read more here.

 
Domainex new starters
New recruits
 

New recruits

Welcome to Alexandra Parker, Carys Thomas, Dillon Rinauro, Graeme Sloan, James Crasswell, James Harnedy, Jesse Peterson, Joe Mason, Junfang Song, Mehul Jesani, Vincent Duong and Industrial Placement Students Holly Madden, Megan Ashley and Soumya who have all recently joined the Domainex team. Find out more about working at Domainex and view the latest vacancies.

New publications

Medicinal Chemistry in Review: Merck Report the Discovery of MK-1468 as a Potent, Brain Penetrant LRRK2 Inhibitor for the Treatment of Parkinson’s Disease

Disruption of Proteostasis by Natural Products and Synthetic Compounds That Induce Pervasive Unfolding of Proteins: Therapeutic Implications

PROTAC platform: Enabling rapid design, characterisation and assessment

 

Identification of novel hit chemotypes by Covalent Fragment Screening and Binding Site Identification using proteolytic digestion and High-Resolution LCMS

Synthesis in Review: A new ortho-phenyl bioisostere and a site selective C-H activation method

Synthesis in Review: Photoredox Enabled Synthesis of Sulfonamides and Derivatives

Upcoming events

Postgraduate Symposium XVII – Biological and Medicinal Chemistry Symposium for Postgraduates 2023
9th January | Oxford, UK

9th Fragment-based Drug Discovery Meeting
3rd March | Cambridge, UK

Start your next project with Domainex

Contact one of our experts today
 
 
 
  Share 
  Tweet 
  Share 
  Forward 
Domainex is a registered company (number 4336899)
Chesterford Research Park
Little Chesterford
Saffron Walden, Essex
CB10 1XL, UK
Preferences  |  Unsubscribe